Intensity Therapeutics Files S-1/A Amendment
Ticker: INTS · Form: S-1/A · Filed: Apr 24, 2025 · CIK: 1567264
| Field | Detail |
|---|---|
| Company | Intensity Therapeutics, Inc. (INTS) |
| Form Type | S-1/A |
| Filed Date | Apr 24, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, s-1/a, biotech
TL;DR
INTENSITY THERAPEUTICS (INTY) AMENDS S-1 FILING - GET READY FOR NEW SHARES
AI Summary
Intensity Therapeutics, Inc. filed an S-1/A amendment on April 24, 2025, for its registration statement. The company, incorporated in Delaware, is in the biological products sector and is headquartered in Shelton, CT. This filing is an amendment to a previous registration, indicating ongoing efforts to register securities for public offering.
Why It Matters
This S-1/A filing signifies that Intensity Therapeutics is actively pursuing a public offering of its securities, which could provide capital for its operations and growth in the biotechnology sector.
Risk Assessment
Risk Level: medium — As a company filing an S-1/A, Intensity Therapeutics is likely in the process of raising capital through a public offering, which inherently carries risks associated with market volatility and the success of their business operations.
Key Numbers
- 333-286683 — SEC File Number (Identifies the specific registration statement with the SEC.)
- 25863626 — Film Number (Internal SEC processing number for the filing.)
Key Players & Entities
- INTENSITY THERAPEUTICS, INC. (company) — Registrant
- April 24, 2025 (date) — Filing Date
- Delaware (jurisdiction) — State of Incorporation
- Shelton, CT (location) — Business Address
- Lewis H. Bender (person) — President, Chief Executive Officer and Chairman
- Jeffrey P. Schultz, Esq. (person) — Counsel
- Ivan K. Blumenthal, Es (person) — Counsel
FAQ
What is the purpose of this S-1/A filing?
This S-1/A filing is an amendment to a previously filed Form S-1 Registration Statement, indicating Intensity Therapeutics, Inc. is updating information related to its planned public offering of securities.
When was this amendment filed?
This amendment was filed with the SEC on April 24, 2025.
Where is Intensity Therapeutics, Inc. headquartered?
Intensity Therapeutics, Inc. is headquartered at 1 Enterprise Drive, Suite 430, Shelton, CT 06484.
Who are the principal officers mentioned in the filing?
Lewis H. Bender is listed as President, Chief Executive Officer and Chairman.
What is the Standard Industrial Classification (SIC) code for Intensity Therapeutics, Inc.?
The SIC code for Intensity Therapeutics, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Details
This Form S-1/A (Form S-1/A) was filed with the SEC on April 24, 2025 by Lewis H. Bender regarding INTENSITY THERAPEUTICS, INC. (INTS).